GILD stock news · Gilead Sciences, Inc.
Get alerts for GILD
Follow Gilead Sciences, Inc. (GILD) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for GILDUBS raised its price target for Gilead Sciences to $195 from $175 and still recommends buying the stock.
Good for GILDUBS raised its price estimate for Gilead and kept its Buy rating. This is a positive analyst view, though the story gives no details about the company's recent results.
Analysts raised their predictions for Gilead Sciences after the company reported better-than-expected earnings last quarter.
NeutralGilead beat analyst estimates for quarterly profit and sales, but lowered its full-year profit forecast while raising its sales forecast. The results point in different directions.
Gilead Sciences shares what happened during their earnings call for the third quarter of 2026.
Good for GILDGilead's base business sales rose 16% year over year, and it raised its full-year revenue forecast by $1.6 billion. Strong drug sales outweigh future Biktarvy price pressure.
Big investors are making moves in 10 health care stocks today.
NeutralThe alert marked Gilead Sciences' put trade bearish. It reports trading activity, not a company change, so it does not change Gilead Sciences' outlook.
Gilead strengthens its plans for treating bowel diseases after a successful mid-stage trial.
Good for GILDGilead's Phase 2 ulcerative colitis trial showed more patients improved on emvistegrast than placebo, supporting its drug pipeline, though longer-term results are still pending.
Vir Biotechnology, Inc. says it sold some of its shares without registering them.
NeutralGilead agreed to work with Vir on 3 possible cancer drugs and buy Vir shares. The filing reports no results or expected value from the drug work, so it does not show a clear change to Gilead's outlook.
Bill Clinton warns that low-cost medicines won't help if people can't get them.
Good for GILDGilead's Bixlenvo received FDA approval after trials showed it kept HIV under control. Wider funding worries could disrupt access, but the article does not connect them to Gilead.